Yumanity Therapeutics is working to identify and develop new disease-modifying therapies that address several illnesses with critical unmet medical needs. The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity Therapeutics is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.